This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sunesis Pharmaceuticals Reports Fourth Quarter And Full-Year 2010 Financial Results

SOUTH SAN FRANCISCO, Calif., March 29, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2010. Net loss for the three months and year ended December 31, 2010 was $10.1 million and $24.6 million, respectively. As of December 31, 2010, cash, cash equivalents and marketable securities totaled $53.4 million, with no debt outstanding.
Sunesis Pharmaceuticals, Inc. Logo
VALOR Logo

"This past year was a landmark year for Sunesis, with our lead program, vosaroxin, moving into a pivotal Phase 3 trial, the VALOR trial, in acute myeloid leukemia," said Daniel Swisher, Chief Executive Officer of Sunesis. "Since the beginning of the fourth quarter, we achieved a number of critical clinical, regulatory, intellectual property and financial objectives, including the launch of the VALOR trial. I am pleased with the pace of site activation and patient enrollment to date. With an improved capital structure and over $53 million in cash at the end of 2010, Sunesis is today well positioned to reach our goal of bringing an important new cancer treatment to patients with an enduring unmet need."

Fourth Quarter 2010 and Recent Highlights

-- Launched Phase 3 VALOR trial of vosaroxin in AML. In December 2010, Sunesis commenced enrollment in its VALOR trial, a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin in combination with cytarabine, a widely used chemotherapy, in patients with relapsed or refractory acute myeloid leukemia (AML). The trial is expected to enroll 450 patients at approximately 100 leading sites in the United States, Canada, Europe, Australia and New Zealand.

-- Granted FDA fast track designation. In February 2011, the FDA granted fast track designation to vosaroxin for the potential treatment of relapsed or refractory AML in combination with cytarabine, providing for the possibility of a "rolling submission" for a marketing application and eligibility for a priority review period by the FDA.

-- Issued important U.S. and European patents covering vosaroxin clinical formulation. In November 2010, Sunesis announced that the United States Patent and Trademark Office (USPTO) had granted U.S. Patent No. 7,829,577, claiming Sunesis' pharmaceutical compositions of vosaroxin. The patent is scheduled to expire in March 2025, and could be eligible for patent term extension beyond this date. Earlier this March, the European Patent Office (EPO) granted European Patent No. 1725233 covering similar claims as described above. Corresponding patent applications are also pending in other major markets throughout the world, including Japan, Australia and Canada.

-- Presented positive Phase 2 data for vosaroxin in AML. In November 2010, Robert Stuart, MD, Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, presented data from Phase 2 clinical trials of vosaroxin in combination with cytarabine in relapsed/refractory AML and as a single agent in frontline elderly AML at the Chemotherapy Foundation Symposium XXVIII. Consistent with results presented at the American Society of Clinical Oncology Annual Meeting in June 2010, vosaroxin achieved clinically meaningful complete remission rates balanced with low all-cause early mortality. Preliminary leukemia-free survival, measured as time from complete remission to relapse or death, was 14.4 months (440 days). Median overall survival was 7.1 months, with 14 patients continuing in survival follow up well beyond this median.

Financial Highlights

-- Cash, cash equivalents and marketable securities totaled $53.4 million as of December 31, 2010, as compared to $4.3 million as of December 31, 2009.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs